ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-17
DOI
10.1038/s41598-020-70924-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genome-wide association studies of endometrial cancer: Latest developments and future directions.
- (2019) Tracy A O'Mara et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study
- (2019) Maarit A. Laaksonen et al. GYNECOLOGIC ONCOLOGY
- Lifetime number of years of menstruation as a risk index for postmenopausal endometrial cancer in the Norwegian Women and Cancer Study
- (2018) Oxana Gavrilyuk et al. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
- Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
- (2018) Michael Y. Choi et al. Cell Stem Cell
- ROR1 and ROR2 play distinct and opposing roles in endometrial cancer
- (2018) C.E. Henry et al. GYNECOLOGIC ONCOLOGY
- Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association
- (2018) Grace Kim et al. MODERN PATHOLOGY
- Double-slit photoelectron interference in strong-field ionization of the neon dimer
- (2018) Maksim Kunitski et al. Nature Communications
- International Patterns and Trends in Endometrial Cancer Incidence, 1978–2013
- (2017) Joannie Lortet-Tieulent et al. JNCI-Journal of the National Cancer Institute
- CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence
- (2017) Katherine C Kurnit et al. MODERN PATHOLOGY
- Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis
- (2017) Claire Henry et al. Oncotarget
- International Patterns and Trends in Endometrial Cancer Incidence, 1978–2013
- (2017) Joannie Lortet-Tieulent et al. JNCI-Journal of the National Cancer Institute
- ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration
- (2016) Sean S. Q. Ma et al. BMC CANCER
- Expression of ROR1 has prognostic significance in triple negative breast cancer
- (2016) Hui-Ping Chien et al. VIRCHOWS ARCHIV
- Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2)
- (2015) H P Yang et al. BRITISH JOURNAL OF CANCER
- miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer
- (2015) HONG TAN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation
- (2015) Jian Yu et al. JOURNAL OF CLINICAL INVESTIGATION
- Ror2 as a Therapeutic Target in Cancer
- (2015) Zufan Debebe et al. PHARMACOLOGY & THERAPEUTICS
- Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion
- (2015) Claire Henry et al. Oncotarget
- Joint Effect of Genotypic and Phenotypic Features of Reproductive Factors on Endometrial Cancer Risk
- (2015) Zhanwei Wang et al. Scientific Reports
- Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma
- (2015) Yanchun Liu et al. PLoS One
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling
- (2014) C. Henry et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy
- (2014) Suping Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The EMT (epithelial-mesenchymal-transition)-related protein expression indicates the metastatic status and prognosis in patients with ovarian cancer
- (2014) Masaaki Takai et al. Journal of Ovarian Research
- Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells
- (2014) C. Berger et al. Cancer Immunology Research
- Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma
- (2013) C. Blake Gilks et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Targeting ROR1 Inhibits Epithelial-Mesenchymal Transition and Metastasis
- (2013) B. Cui et al. CANCER RESEARCH
- Activation of Wnt5a-Ror2 signaling associated with epithelial-to-mesenchymal transition of tubular epithelial cells during renal fibrosis
- (2013) Xin Li et al. GENES TO CELLS
- Tumor Mismatch Repair Immunohistochemistry and DNA MLH1 Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 60 Years Optimizes Triage for Population-Level Germline Mismatch Repair Gene Mutation Testing
- (2013) Daniel D. Buchanan et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers
- (2012) Suping Zhang et al. AMERICAN JOURNAL OF PATHOLOGY
- The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis
- (2012) Caroline E. Ford et al. INTERNATIONAL JOURNAL OF CANCER
- Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis
- (2012) Ming Geng WORLD JOURNAL OF GASTROENTEROLOGY
- Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis
- (2011) A. Gentile et al. CANCER RESEARCH
- Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type
- (2010) B. A. Clarke et al. JOURNAL OF CLINICAL PATHOLOGY
- Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer
- (2010) Ester Lara et al. Molecular Cancer
- Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma
- (2009) Kazuhito Morioka et al. CANCER SCIENCE
- Body size, adult BMI gain and endometrial cancer risk: the multiethnic cohort
- (2009) Sungshim Lani Park et al. INTERNATIONAL JOURNAL OF CANCER
- Ror2 Receptor Requires Tyrosine Kinase Activity to Mediate Wnt5A Signaling
- (2009) Amanda Mikels et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma
- (2009) T M Wright et al. ONCOGENE
- Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia
- (2008) S. Baskar et al. CLINICAL CANCER RESEARCH
- Receptor Tyrosine Kinase Ror2 Mediates Wnt5a-induced Polarized Cell Migration by Activating c-Jun N-terminal Kinase via Actin-binding Protein Filamin A
- (2008) Akira Nomachi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a
- (2008) T. Fukuda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started